BACKGROUND: Limited treatment options have been available for people with HIV who have had virological failure of the three original classes of HIV antiretroviral drugs-so-called triple-class virological failure (TCVF). However, introduction of new drugs and drug classes might have improved outcomes. We aimed to assess trends in virological and clinical outcomes for individuals with TCVF in 2000-09. METHODS: In our cohort study, we analysed data for adults starting antiretroviral therapy from 1998 in cohorts participating in the PLATO II project, which is part of COHERE, a collaboration of European cohorts. TCVF was defined as virological failure to at least two nucleoside reverse transcriptase inhibitors, one non-nucleoside reverse-transcriptase inhibitor, and one ritonavir-boosted protease inhibitor, with virological failure of a drug defined as one viral-load measurement of greater than 500 copies per mL after at least 4 months of continuous use. We used multivariable generalised estimating equation logistic models and Poisson regression models to study trends in virological suppression and incidence of AIDS or death after TCVF. We adjusted for sex, transmission group, age, AIDS status, CD4 cell count, plasma viral loads at TCVF, achievement of virological response (<50 copies per mL), and number of drug failures before TCVF. FINDINGS: 28 of 33 cohorts in COHERE contributed data to the PLATO II project, of which four had no participants eligible for inclusion in this study. 2476 (3%) of 91 764 participants from the remaining 24 cohorts had TCVF and at least one viral load measurement in 2000-09. The proportion of patients with virological response after TCVF increased from 19·5% in 2000 to 57·9% in 2009 (adjusted p<0·0001). Incidence of AIDS decreased from 7·7 per 100 person-years in 2000-02 to 2·3 in 2008 and 1·2 in 2009 (adjusted p<0·0001). Mortality decreased from 4·0 per 100 person-years between 2000 and 2002 to 1·9 in 2007 and 1·4 in 2008 (unadjusted p=0·023), but the trend was not significant after adjustment (p=0·22). INTERPRETATION: A substantial improvement in viral load suppression and accompanying decrease in the rates of AIDS in people after extensive failure to drugs from the three original antiretroviral classes during 2000-09 was probably mainly driven by availability of newer drugs with better tolerability and ease of use and small cross-resistance profiles, suggesting the public health benefit of the introduction of new drugs.
|Data di pubblicazione:||2012|
|Titolo:||Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.|
|Autore/i:||Costagliola D; Ledergerber B; Torti C; van Sighem A; Podzamczer D; Mocroft A; Dorrucci M; Masquelier B; de Luca A; Jansen K; De Wit S; Obel N; Fätkenheuer G; Touloumi G; Mussini C; Castagna A; Stephan C; Garcia F; Zangerle R; Duval X; Pérez-Hoyos S; Meyer L; Ghosn J; Fabre-Colin C; Kjaer J; Chene G; Fabre-Colin C; Kjaer J; Grarup J; Lodwick R; Phillips A.|
|Digital Object Identifier (DOI):||10.1016/S1473-3099(11)70248-1|
|Codice identificativo ISI:||WOS:000299656000020|
|Codice identificativo Scopus:||2-s2.0-84856233618|
|Citazione:||Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. / Costagliola D; Ledergerber B; Torti C; van Sighem A; Podzamczer D; Mocroft A; Dorrucci M; Masquelier B; de Luca A; Jansen K; De Wit S; Obel N; Fätkenheuer G; Touloumi G; Mussini C; Castagna A; Stephan C; Garcia F; Zangerle R; Duval X; Pérez-Hoyos S; Meyer L; Ghosn J; Fabre-Colin C; Kjaer J; Chene G; Fabre-Colin C; Kjaer J; Grarup J; Lodwick R; Phillips A.. - In: THE LANCET INFECTIOUS DISEASES. - ISSN 1473-3099. - STAMPA. - 12(2012), pp. 119-127.|
|Tipologia||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris